After the "Silicone Rubber War," GeneChem faces growth anxiety for the first time.

```

In mid-2025, an "industry-level public opinion dispute" with Bloomage Biotech put Giant Biotech in the eye of the storm.

This dispute was not only a battle for discourse between two major ingredient tracks—recombinant collagen and hyaluronic acid—but also dragged Giant Biotech into a whirlpool of controversy over the alleged underreported collagen content in its core brand, Cofumei.

Although the storm finally ended with the conclusion that different testing standards led to differing test results, it still impacted Giant Biotech’s performance to some extent.

Coupled with increasingly fierce industry competition, Giant Biotech delivered a 2025 report card with both revenue and profit declining: the company’s revenue for the period was 5.518 billion yuan, a slight year-on-year decrease of 0.37%, and net profit was 1.914 billion yuan, down 7.15% year-on-year.

Looking at specific business segments, Giant Biotech’s core brands showed clear differentiation in 2025:

As the absolute main force contributing over 80% of revenue, Cofumei achieved sales revenue of 4.47 billion yuan in 2025, a year-on-year decrease of 1.6%.

According to the financial report, this was mainly due to external shocks and intensified industry price competition.

Combined with the mid-2025 public opinion dispute, doubts over the normative claims about Cofumei’s products have, to some extent, weakened consumer trust and had a substantial impact on this flagship brand’s sales.

However, another skincare brand, ColiGold, continued to maintain a growth trend, recording revenue of 918 million yuan in 2025, up 9.2% year-on-year.

This was mainly due to active expansion of online channels and the successful launch of the upgraded blockbuster product "Big Mask King 3.0."

After enduring the pain of 2025, Giant Biotech has clearly stated its goal for 2026 is to return to growth.

According to the strategic layout revealed in the financial report, Giant Biotech’s future core growth points will focus on strengthening its medical aesthetics business, expanding applications for ingredients beyond collagen, incubating new brands, and expanding omnichannel distribution, among others.

Perhaps the most notable move is in the medical aesthetics business.

Since 2025, Giant Biotech’s recombinant type I a1 subtype collagen lyophilized fiber and recombinant type I a1 subtype collagen & sodium hyaluronate compound solution products have successively been approved for market launch by the national drug regulator, marking its formal entry into the medical aesthetics sector.

The “collagen vs hyaluronic acid war” of 2025 was not only a PR crisis but more like an industry "coming of age ceremony;" it exposed Giant Biotech’s shortcomings on its fast track, while also prompting the company to improve its product standards and norms.

In 2026, whether Giant Biotech, armed with its Class III medical device “trump cards,” can leverage the medical aesthetics sector for a successful turnaround and regain its high growth momentum remains to be seen, as the market watches closely.

Risk Disclaimer and Limitation of LiabilityThe market carries risks, and investments need to be approached with caution. This article does not constitute individual investment advice and does not take into account the specific investment goals, financial situation, or needs of any particular user. Users should consider whether any opinions, views, or conclusions in this article are appropriate to their particular situation. Investment decisions are made at one's own risk. ```